Stay updated on Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial

Sign up to get notified when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The clinical trial record for the study is now available, with details on its design, pembrolizumab and ibrutinib treatment, eligibility, and measured outcomes. The record indicates the study was terminated and is no longer recruiting participants.
    Difference
    47%
    Check dated 2026-11-09T04:50:53.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0, while the page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T02:56:29.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A sitewide notice announces NIH’s stated transition from “Artificial Intelligence” to “Super Intelligence.” The clinical study record remains inaccessible with a 403 error.
    Difference
    1%
    Check dated 2026-10-26T04:44:17.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-19T06:49:57.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-12T02:59:20.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden error, replacing the typical study record content with an access-denied message. This indicates restricted access to the page rather than a substantive update to the study information.
    Difference
    18%
    Check dated 2026-09-21T00:57:49.000Z thumbnail image

Stay in the know with updates to Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.